Advertisement

CMV Prevention and Treatment in Transplantation: What’s New in 2019

  • Anat Stern
  • Genovefa A. PapanicolaouEmail author
Transplant and Oncology (M Ison, N Theodoropoulos, and S Pergam, Section Editors)
  • 230 Downloads
Part of the following topical collections:
  1. Topical Collection on Transplant and Oncology

Abstract

Purpose of Review

Transplant recipients are at risk for cytomegalovirus (CMV) infection and associated morbidity and mortality. We summarize recently introduced or currently investigated modalities for prevention and treatment of CMV infection in hematopoietic cell (HCT) and solid organ transplant (SOT) recipients.

Recent Findings

Letermovir was recently approved for CMV prevention in HCT recipients. Data from real world studies support its role to improve outcomes in this population. Letermovir is currently under investigation for broader patient populations and indications. Maribavir is in late stages of development for CMV treatment and may provide a safer alternative to currently available anti-CMV drugs. Promising CMV vaccine candidates and adoptive cell therapy approaches are under evaluation. CMV immune monitoring assays are predicted to play a more central role in our clinical decision making.

Summary

In recent years, major advances have been made in CMV prevention and treatment in transplant recipients. Rigorous research is ongoing and is anticipated to further impact our ability to improve outcomes in this population.

Keywords

Cytomegalovirus (CMV) Hematopoietic cell transplant (HCT) Solid organ transplant (SOT) Cell-mediated immunity (CMI) Prophylaxis Preemptive treatment 

Notes

Compliance with Ethical Standards

Conflict of Interest

Anat Stern declares that she has no conflict of interest.

Genovefa Papanicolaou has been an investigator for Astellas Pharma, Chimerix Inc., Merck & Co, and Shire and has received funding and/or other fees from Astellas Pharma, Chimerix Inc., Merck & Co, Clinigen, Ideogen, and Oxford Immunotech.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

  1. 1.
    Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–38 [cited 2019 Jul 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26884374.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Fisher RA. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation. Transpl Infect Dis. 2009;11(3):195–202.  https://doi.org/10.1111/j.1399-3062.2009.00372.x.CrossRefPubMedGoogle Scholar
  3. 3.
    Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119–27 [cited 2019 Jul 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26947200.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Sagedal S, Hartmann A, Nordal KP, Osnes K, Leivestad T, Foss A, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int. 2004;66(1):329–37 [cited 2019 Sep 3]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0085253815500355.PubMedGoogle Scholar
  5. 5.
    Chan ST, Logan AC. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: why the quest for meaningful prophylaxis still matters. Blood Rev. 2017;31(3):173–83 [cited 2019 Jul 4]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0268960X16300492.PubMedGoogle Scholar
  6. 6.
    Stern M, Hirsch H, Cusini A, van Delden C, Manuel O, Meylan P, et al. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation. 2014;98(9):1013–8 [cited 2019 Jul 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24837540.PubMedGoogle Scholar
  7. 7.
    Litjens NHR, van der Wagen L, Kuball J, Kwekkeboom J. Potential beneficial effects of cytomegalovirus infection after transplantation. Front Immunol. 2018;9:389 [cited 2019 Jul 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29545802.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Merck Sharp & Dohme Corp. PREVYMIS™ (Letermovir) Prescribing Information. [cited 2019 Jul 9]. Available from: www.fda.gov/medwatch.
  9. 9.
    Yong MK, Lewin SR, Manuel O. Immune monitoring for CMV in transplantation. Curr Infect Dis Rep. 2018;20(4):4 [cited 2019 Jul 6]. Available from: http://link.springer.com/10.1007/s11908-018-0610-4.PubMedGoogle Scholar
  10. 10.
    Preiksaitis JK, Hayden RT, Tong Y, Pang XL, Fryer JF, Heath AB, et al. Are we there yet? Impact of the first international standard for cytomegalovirus DNA on the harmonization of results reported on plasma samples. Clin Infect Dis. 2016;63(5):583–9 [cited 2019 Jul 9]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27307504.PubMedGoogle Scholar
  11. 11.
    Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Cytomegalovirus in Transplantation: Developing Drugs to Treat or Prevent Disease Guidance for Industry DRAFT GUIDANCE. 2018. [cited 2019 Jul 11]. Available from: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
  12. 12.
    Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, et al. The third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900–31 [cited 2019 Jul 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29596116.PubMedGoogle Scholar
  13. 13.
    Hodson EM, Ladhani M, Webster AC, Strippoli GF, Craig JC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013.  https://doi.org/10.1002/14651858.CD003774.pub4.
  14. 14.
    Owers DS, Webster AC, Strippoli GF, Kable K, Hodson EM. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013;(2):CD005133 [cited 2019 Jul 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23450558.
  15. 15.
    Singh N, Winston D, Razonable RR, Lyon III GM, Silveira FP, Wagener M, et al. Preemptive therapy (PET) vs. prophylaxis for prevention of cytomegalovirus (CMV) disease in high-risk donor seropositive/recipient seronegative (D+R−) liver transplant recipients (LTR): A NIH-sponsored, randomized, controlled, multicenter trial. In: Open Forum Infectious Diseases. Idsa; 2018 [cited 2019 Sep 3]. p. S766–S766. Available from: https://idsa.confex.com/idsa/2018/webprogram/Paper74389.html.PubMedCentralGoogle Scholar
  16. 16.
    Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients—guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019:e13512 [cited 2019 Sep 3]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30817026.
  17. 17.
    Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. Chêne G, editor. PLoS One 2009;4(5):e5512.  https://doi.org/10.1371/journal.pone.0005512.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis. 2003;3(10):611–23 [cited 2019 Feb 20]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1473309903007709.PubMedGoogle Scholar
  19. 19.
    Bueno J, Ramil C, Green M. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients. Pediatr Drugs. 2002;4(5):279–90 [cited 2019 Jul 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11994033.Google Scholar
  20. 20.
    Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118(3):173 [cited 2019 Jul 11]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8380242.PubMedGoogle Scholar
  21. 21.
    Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11(4):284–92 [cited 2019 Jul 5]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S147330991170024X.PubMedGoogle Scholar
  22. 22.
    Winston DJ, Saliba F, Blumberg E, Abouljoud M, Garcia-Diaz JB, Goss JA, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012;12(11):3021–30.  https://doi.org/10.1111/j.1600-6143.2012.04231.x.CrossRefPubMedGoogle Scholar
  23. 23.
    Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, et al. A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25(2):369–81 [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30292744.PubMedGoogle Scholar
  24. 24.
    Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010;54(3):1290–7 [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20047911.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–44 [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29211658.PubMedGoogle Scholar
  26. 26.
    Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, et al. A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic-cell transplantation. Clin Infect Dis. 2019; [cited 2019 Jul 5]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/31179485.
  27. 27.
    Kropeit D, von Richter O, Stobernack H-P, Rübsamen-Schaeff H, Zimmermann H. Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects. Clin Pharmacol Drug Dev. 2018;7(1):9–21.  https://doi.org/10.1002/cpdd.388.CrossRefPubMedGoogle Scholar
  28. 28.
    Rapid CS. In Vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance. Antimicrob Agents Chemother. 2015;59(10):6588–93 [cited 2019 Jul 9]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26259791.Google Scholar
  29. 29.
    Cherrier L, Nasar A, Goodlet KJ, Nailor MD, Tokman S, Chou S. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant. 2018;18(12):3060–4.  https://doi.org/10.1111/ajt.15135.CrossRefPubMedGoogle Scholar
  30. 30.
    Hodowanec A, Komatsu T, Singer M, Smith F, Valappil T, O’Rear JMJBD. Late Cmv Infection Following Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients. In: American Transplant Congress, Seattle Washington, June 8, 2018 [Internet]. [cited 2019 Jul 10]. Available from: https://atcmeeting.org/abstracts.
  31. 31.
    Robin C, Ducastelle-Lepretre S, Thiebaut A, de la Tour RP, Ceballos P, Masure M, et al. Letermovir for prophylaxis of cytomegalovirus (CMV) infection or disease in allogeneic hct recipients: experience of secondary prophylaxis in the French compassionate program. Bone Marrow Transplant. 2019;54(S1):144–619 [cited 2019 Jul 9]. Available from: http://www.nature.com/articles/s41409-019-0559-4.Google Scholar
  32. 32.
    McVoy MA. Cytomegalovirus vaccines. Clin Infect Dis. 2013;57(suppl_4):S196–9 [cited 2019 Jul 5]. Available from: http://academic.oup.com/cid/article/57/suppl_4/S196/494333/Cytomegalovirus-Vaccines.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377(9773):1256–63 [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21481708.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Baraniak I, Kropff B, Ambrose L, McIntosh M, McLean GR, Pichon S, et al. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies. Proc Natl Acad Sci U S A. 2018;115(24):6273–8 [cited 2019 Jul 5]. Available from: http://www.pnas.org/lookup/doi/10.1073/pnas.1800224115.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Smith L, Wloch M, Chaplin J, Gerber M, Rolland A, Smith LR, et al. Clinical development of a cytomegalovirus DNA vaccine: from product concept to pivotal phase 3 trial. Vaccines. 2013;1(4):398–414 [cited 2019 Jul 9]. Available from: http://www.mdpi.com/2076-393X/1/4/398.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Diamond DJ, La Rosa C, Chiuppesi F, Contreras H, Dadwal S, Wussow F, et al. A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection. Expert Rev Vaccines. 2018;17(10):889–911 [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30246580.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Ávila SG, Gaminde AI, Escamilla MS. EBMT Abstracts 2019 Infectious complications. 2019.Google Scholar
  38. 38.
    Nakamura R, La Rosa C, Longmate J, Drake J, Slape C, Zhou Q, et al. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol. 2016;3(2):e87–98 [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26853648.PubMedGoogle Scholar
  39. 39.
    La Rosa C, Longmate J, Martinez J, Zhou Q, Kaltcheva TI, Tsai W, et al. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. Blood. 2017;129(1):114–25 [cited 2019 Jul 5]. Available from: http://www.bloodjournal.org/lookup/doi/10.1182/blood-2016-07-729756.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Pollack M, Heugel J, Xie H, Leisenring W, Storek J, Young J-A, et al. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2011;17(5):664–73 [cited 2019 Jul 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20699126.PubMedGoogle Scholar
  41. 41.
    Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood. 1999;93(5):1781–2 [cited 2019 Jul 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10084817.PubMedGoogle Scholar
  42. 42.
    Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith AA, Davis MG, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002;46(8):2365–72 [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12121906.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Koszalka GW, Johnson NW, Good SS, Boyd L, Chamberlain SC, Townsend LB, et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 2002;46(8):2373–80 [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12121907.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Maertens J, Cordonnier C, Jaksch P, Poiré X, Wu JJ, Wijatyk A, et al. Maribavir versus valganciclovir for preemptive treatment of cytomegalovirus (CMV) viremia: a randomized, dose-ranging, phase 2 study among hematopoietic stem cell transplant (SCT) and solid organ transplant (SOT) recipients. In Idsa; 2016. [cited 2019 Jul 5]. Available from: https://idsa.confex.com/idsa/2016/webprogram/Paper56176.html.
  45. 45.
    Shmueli E, Or R, Shapira MY, Resnick IB, Caplan O, Bdolah-Abram T, et al. High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation. J Infect Dis. 2014;209(4):557–61 [cited 2019 Jul 4]. Available from: https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/jit475.PubMedGoogle Scholar
  46. 46.
    Van Leer Buter CC, de Voogd DWK, Blokzijl H, de Joode AAE, Berger SP, Verschuuren EAM, et al. Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands. J Antimicrob Chemother. 2019; [cited 2019 Jul 4]. Available from: https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkz196/5489804.
  47. 47.
    Minces LR, Nguyen MH, Mitsani D, Shields RK, Kwak EJ, Silveira FP, et al. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens. Antimicrob Agents Chemother. 2014;58(1):128–35 [cited 2019 Jul 9]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24145525.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 2002;35(7):866–72 [cited 2019 Jul 9]. Available from: https://academic.oup.com/cid/article-lookup/doi/10.1086/342385.PubMedGoogle Scholar
  49. 49.
    Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, et al. Definitions of Resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2019;68(8):1420–6 [cited 2019 Jul 9]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30137245.PubMedGoogle Scholar
  50. 50.
    Chou S. Approach to drug-resistant cytomegalovirus in transplant recipients. Curr Opin Infect Dis. 2015;28(4):293–9 [cited 2019 Jul 9]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26098499.PubMedPubMedCentralGoogle Scholar
  51. 51.
    El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood. 2016;128(23):2624–36 [cited 2019 Jul 9]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27760756.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Papanicolaou GA, Silveira FP, Langston AA, Pereira MR, Avery RK, Uknis M, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin Infect Dis. 2019;68(8):1255–64 [cited 2019 Jul 5]. Available from: https://academic.oup.com/cid/article/68/8/1255/5133438.PubMedGoogle Scholar
  53. 53.
    Stoelben S, Arns W, Renders L, Hummel J, Mühlfeld A, Stangl M, et al. Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transpl Int. 2014;27(1):77–86.  https://doi.org/10.1111/tri.12225.CrossRefPubMedGoogle Scholar
  54. 54.
    Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011;11(5):1079–84.  https://doi.org/10.1111/j.1600-6143.2011.03530.x.CrossRefPubMedGoogle Scholar
  55. 55.
    Phoompoung P, Ferreira VH, Tikkanen J, Husain S, Viswabandya A, Kumar D, et al. Letermovir as salvage therapy for CMV infection in transplant recipients. Transplantation. 2019;1. [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31107821.
  56. 56.
    Turner N, Strand A, Grewal DS, Cox G, Arif S, Baker AW, et al. Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis. Antimicrob Agents Chemother. 2019;63(3). [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30642941.
  57. 57.
    Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 1994;83(7):1971–9 [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8142663.PubMedGoogle Scholar
  58. 58.
    Riddell SR, Watanabe K, Goodrich J, Li C, Agha M, Greenberg P. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257(5067):238–41 [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1352912.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116(20):4360–7 [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20625005.PubMedGoogle Scholar
  60. 60.
    Micklethwaite KP, Clancy L, Sandher U, Hansen AM, Blyth E, Antonenas V, et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood. 2008;112(10):3974–81 [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18768783.PubMedGoogle Scholar
  61. 61.
    Einsele H. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99(11):3916–22 [cited 2019 Jul 5]. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood.V99.11.3916.PubMedGoogle Scholar
  62. 62.
    Zhao X-Y, Pei X-Y, Chang Y-J, Yu X-X, Xu L-P, Wang Y, et al. First-line therapy with donor-derived HCMV-specific T cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic stem cell transplantation. Clin Infect Dis. 2019. [cited 2019 Jul 5]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/31067570.
  63. 63.
    Prockop S, Doubrovina E, Hasan AN, Dahi PB, Giralt S, Koehne G, et al. Third party CMV-specific cytotoxic T cells for treatment of antiviral resistant CMV infection after hematopoietic stem cell transplant. Blood. 2016;128(22). [cited 2019 Jul 5]. Available from: http://www.bloodjournal.org/content/128/22/61?sso-checked=true.Google Scholar
  64. 64.
    O’Reilly RJ, Prockop S, Hasan AN, Koehne G, Doubrovina E. Virus-specific T-cell banks for “off the shelf” adoptive therapy of refractory infections. Bone Marrow Transplant. 2016;51(9):1163–72 [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27042851.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, et al. Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2017;35(31):3547–57 [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28783452.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Egli A, Humar A, Kumar D. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis. 2012;55(12):1678–89 [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22990848.PubMedGoogle Scholar
  67. 67.
    Kaminski H, Fishman JA. The cell biology of cytomegalovirus: implications for transplantation. Am J Transplant. 2016;16(8):2254–69.  https://doi.org/10.1111/ajt.13791.CrossRefPubMedGoogle Scholar
  68. 68.
    Pierucci P, Malouf M, Glanville AR, Beagley L, Smith C, Khanna R. Novel autologous T-cell therapy for drug-resistant cytomegalovirus disease after lung transplantation. J Hear Lung Transplant. 2016;35(5):685–7 [cited 2019 Jul 6]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27083238.Google Scholar
  69. 69.
    Brestrich G, Zwinger S, Fischer A, Schmück M, Röhmhild A, Hammer MH, et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant. 2009;9(7):1679–84 [cited 2019 Jul 6]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19459791.PubMedGoogle Scholar
  70. 70.
    Kontoyiannis DP, Patterson TF. Diagnosis and treatment of invasive fungal infections in the cancer patient: recent progress and ongoing questions. Clin Infect Dis. 2014;59(Suppl 5):S356–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25352631.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Macesic N, Langsford D, Nicholls K, Hughes P, Gottlieb DJ, Clancy L, et al. Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient. Am J Transplant. 2015;15(3):827–32 [cited 2019 Jul 6]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25648555.PubMedGoogle Scholar
  72. 72.
    Gliga S, Korth J, Krawczyk A, Wilde B, Horn PA, Witzke O, et al. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients. J Clin Virol. 2018;105:91–6 [cited 2019 Jul 6]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1386653218301574.PubMedGoogle Scholar
  73. 73.
    Lee H, Park KH, Ryu JH, Choi A-R, Yu JH, Lim J, et al. Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients. Akatsuka Y, editor. PLoS One. 2017;12(12):e0189488. [cited 2019 Jul 6]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29232714.
  74. 74.
    Jarque M, Melilli E, Crespo E, Manonelles A, Montero N, Torras J, et al. CMV-specific cell-mediated immunity at 3-month prophylaxis withdrawal discriminates D+/R+ kidney transplants at risk of late-onset CMV infection regardless the type of induction therapy. Transplantation. 2018;102(11):e472–80 [cited 2019 Jul 10]. Available from: http://insights.ovid.com/crossref?an=00007890-201811000-00033.PubMedGoogle Scholar
  75. 75.
    Cantisán S, Lara R, Montejo M, Redel J, Rodríguez-Benot A, Gutiérrez-Aroca J, et al. Pretransplant interferon-γ secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant. 2013;13(3):738–45.  https://doi.org/10.1111/ajt.12049.CrossRefPubMedGoogle Scholar
  76. 76.
    Bestard O, Crespo E, Stein M, Lúcia M, Roelen DL, de Vaal YJ, et al. Cross-validation of IFN-γ Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. Am J Transplant. 2013;13(7):1880–90 [cited 2019 Jul 6]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23763435.PubMedGoogle Scholar
  77. 77.
    El Haddad L, Ariza-Heredia E, Shah DP, Jiang Y, Blanchard T, Ghantoji SS, et al. The ability of a cytomegalovirus ELISPOT assay to predict outcome of low-level CMV reactivation in hematopoietic cell transplant recipients. J Infect Dis. 2019;219(6):898–907 [cited 2019 Jul 10]. Available from: https://academic.oup.com/jid/article/219/6/898/5122855.PubMedGoogle Scholar
  78. 78.
    Walker S, Fazou C, Crough T, Holdsworth R, Kiely P, Veale M, et al. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis. 2007;9(2):165–70.  https://doi.org/10.1111/j.1399-3062.2006.00199.x.CrossRefPubMedGoogle Scholar
  79. 79.
    Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013;56(6):817–24 [cited 2019 Jul 6]. Available from: https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/cis993.PubMedGoogle Scholar
  80. 80.
    Kumar D, Mian M, Singer L, Humar A. An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation. Am J Transplant. 2017;17(9):2468–73 [cited 2019 Jul 6]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28500691.PubMedGoogle Scholar
  81. 81.
    Westall GP, Cristiano Y, Levvey BJ, Whitford H, Paraskeva MA, Paul E, et al. A randomized study of quantiferon CMV-directed versus fixed-duration valganciclovir prophylaxis to reduce late CMV after lung transplantation. Transplantation. 2019;103(5):1005–13 [cited 2019 Jul 10]. Available from: http://insights.ovid.com/crossref?an=00007890-900000000-96365.PubMedGoogle Scholar
  82. 82.
    Singh N, Gayowski T, Wagener MM, Zeevi A. T-helper cell responses in liver transplant recipients: correlation with cytomegalovirus and other major infections. Transpl Infect Dis. 2004;6(2):93–6 [cited 2019 Jul 6]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15522114.PubMedGoogle Scholar
  83. 83.
    Lilleri D, Gerna G, Zelini P, Chiesa A, Rognoni V, Mastronuzzi A, et al. Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation. Perez-Martinez A, editor. PLoS One. 2012;7(7):e41648.  https://doi.org/10.1371/journal.pone.0041648.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Lilleri D, Gerna G, Fornara C, Chiesa A, Comolli G, Zecca M, et al. Human cytomegalovirus-specific T cell reconstitution in young patients receiving T cell-depleted, allogeneic hematopoietic stem cell transplantation. J Infect Dis. 2009;199(6):829–36 [cited 2019 Jul 6]. Available from: https://academic.oup.com/jid/article-lookup/doi/10.1086/597123.PubMedGoogle Scholar
  85. 85.
    Widmann T, Sester U, Gärtner BC, Schubert J, Pfreundschuh M, Köhler H, et al. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. Stevenson PG, editor. PLoS One. 2008;3(11):e3634.  https://doi.org/10.1371/journal.pone.0003634.PubMedPubMedCentralGoogle Scholar
  86. 86.
    Camargo JF, Wieder ED, Kimble E, Benjamin CL, Kolonias DS, Kwon D, et al. Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation. Blood. 2019;133(8):867–77 [cited 2019 Jul 10]. Available from: http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-10-878918.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Infectious Disease Service, Memorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations